{"id":"W3212498888","doi":"10.1182/blood-2021-144730","title":"Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Medicine; Dosing; Pharmacokinetics; Clinical trial; Placebo; Internal medicine; Clinical endpoint; Pharmacodynamics; Adverse effect; Gastroenterology; Pharmacology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001784735,0.000190574,0.0003947178,0.00003611454,0.0001258741,0.00003368644,0.0001684061,0.0001058163,0.00002247741],"category_scores_gemma":[0.0003809488,0.0001239127,0.0000474819,0.0002202466,0.0001415452,0.00007813612,0.000241462,0.0003256284,0.00000346265],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001623163,"about_ca_system_score_gemma":0.000377563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002913976,"about_ca_topic_score_gemma":0.00008449014,"domain_scores_codex":[0.9984153,0.000150698,0.0005010293,0.000402679,0.0002700996,0.0002602267],"domain_scores_gemma":[0.9989805,0.00009878288,0.0001402302,0.0004697092,0.00008560529,0.0002251323],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8574719,0.1092233,0.004000223,0.0002837143,0.0003195594,0.001826365,0.004581393,0.00001738018,0.005076765,0.00001881237,0.0003747762,0.01680573],"study_design_scores_gemma":[0.9830841,0.002963682,0.005006613,0.001658815,0.0008289756,0.000009757578,0.0009942529,0.0003588676,0.004088382,0.0000109545,0.0007807505,0.0002147943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944248,0.001426938,0.00001413684,0.001223794,0.0001550427,0.001219739,0.0002861265,0.00001802096,0.00123138],"genre_scores_gemma":[0.9985215,0.0005140186,0.0001462055,0.0003669289,0.0001089195,0.00001008828,0.0001789416,0.00002533,0.0001280526],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1256122,"threshold_uncertainty_score":0.5053015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02047883934578233,"score_gpt":0.29530869868982,"score_spread":0.2748298593440376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}